Molecular Diagnostics & Genetics

6.25 CME Credits

5 February 2020
Riyadh Room, Za'abeel Hall 3, Dubai World Trade Centre

Genomic testing represents a change in the continuum of patient care including establishment of the diagnosis, prognosis and tailoring therapy. It has ushered in a new period in medicine triggering a revolution that is evidence-based whereby medicine is personalised, predictive, preventive, and participatory. The translation of these emerging data and concepts to the clinical setting will be an exciting area of development for the molecular pathology community and will be addressed in this conference.

Key topics:

  • Genome mapping projects
  • Preimplantation genetic screening
  • CAR-T cell therapy
  • Monitoring biological therapies
  • Biological Mass Spectrometry
  • Phenomic diagnostics

Benefits of attending:

  • Describe the role of preimplantation genetic screening
  • Review key principles of CAR-T cell therapy
  • Identify the latest guidelines and regulatory updates in phenomic diagnostics
  • Review the latest technology and its applications in the field of molecular diagnostics

Chair:

Prof Ray Iles, Dean – College of Health Sciences, Abu Dhabi University, Abu Dhabi, UAE

Activity director:

Dr Fadi W. Abdul-Karim, Professor Emeritus, Cleveland Clinic Lerner School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA

Speaker faculty:

Dr Ahmad Abou Tayoun, Head of Genomic Diagnostics, Al Jalila Specialty Hospital, Dubai, UAE
 
Prof Jo Martin, President, Royal College of Pathologists; Clinical Director of Diagnostics and Therapeutics Directorate, Barts & The London NHS Trust, London, UK
 
Prof Leif Groop, Senior Professor, Lund University, Sweden; Research Director, Institute of Molecular Medicine Finland (FIMM) Helsinki, Finland
 
Dr Masafumi Inoue, Senior Research Scientist & Group Leader, Molecular Diagnostics Group, Experimental Therapeutics Centre, Nanos, Singapore
 
Prof Ricardo Pais, Data Scientist, MAPSciences, Lisbon, Portugal
 
Prof Stephen Harding, Chief Scientific Officer, The Binding Site Group, Birmingham, UK
 
Dr Val V. Zvereff, Head of the Molecular Diagnostic Department, National Reference Laboratory, Abu Dhabi, UAE